Prashant Tandon

Prashant Tandon is the Co-Founder and CEO of Tata 1mg, one of India’s largest digital healthcare platforms. Tata Group’s own profile describes him as a leading entrepreneur in India’s digital healthcare space since 2009 and says he built Tata 1mg into India’s largest digital healthcare platform, spanning medicines, lab tests, consultations, digital channels, physical centres, and institutional partners.

Before 1mg, Tandon worked at Hindustan Lever Ltd. as a Production Manager and later at McKinsey & Company as a Summer Associate and Senior Associate. In 2010, he left McKinsey to start HealthKart, a Gurgaon-based health commerce company backed by Sequoia Capital, Omidyar Network, and Kae Capital, according to The Org’s profile.

In 2015, Tandon started 1mg. The company originated as a healthcare transparency platform around medicines, drug substitutes, side effects, interactions, and usage information, then expanded into an integrated healthcare platform combining pharmacy, labs, doctors, and health records. In June 2021, Tata Digital acquired a majority stake in 1mg, after which the business became Tata 1mg.

Tandon has an MBA from Stanford Graduate School of Business and a B.Tech in Chemical Engineering from IIT Delhi, according to The Org. His public writing and interviews consistently frame healthcare as a consumer-led, trust-sensitive, regulation-heavy category where technology can improve access, transparency, and quality.

• Tandon’s clearest stated thesis is around digital healthcare in India: he wrote that “healthcare would be the space most impacted by digital India,” through better knowledge access, clarity, and transparency.
• He focuses on healthcare models where the patient is the core user and payer. In an ETHealthWorld interview, he said India offers a larger opportunity for “models that are more consumer centric” because much of healthcare spend is consumer-led.
• He appears most aligned with companies solving access, transparency, quality, and trust problems in healthcare, especially e-pharmacy, diagnostics, telemedicine, health records, specialty pharma, and AI/data-science tools for doctors and patient outcomes.
• His bar for healthcare companies is operationally demanding: Tata 1mg’s stated strategy emphasizes trust, quality, integrated platforms, lifecycle care, personalization, compliance, and supply-chain authenticity.
• No public, independently verified check size or formal personal angel-investing stage mandate was found beyond the provided stub indicating seed-stage angel activity.